A few serum biomarkers for lung cancer are currently under investigation, including Cyfra 21.1 and CEA for NSCLC and neuron-specific enolase (NSE) for SCLC [12,26,27]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.